Publications

Dose Selection of Antithrombin (Recombinant)

Paidas M.J., Frieling J., de Jongh J., Drenth H.J., and Streisand J., Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149], Obstet Gynecol., 125(Suppl 1): 52S., 2015. [Link to publication]

Evaluation of the Long-Term Durability and Glycemic Control of Fasting Plasma Glucose and Glycosylated Hemoglobin

Stringer F., DeJongh J., Enya K., Koumura E., Danhof M. and Kaku K., Evaluation of the Long-Term Durability and Glycemic Control of Fasting Plasma Glucose and Glycosylated Hemoglobin for Pioglitazone in Japanese Patients with Type 2 Diabetes, Diabetes Technol Ther, 22: 22, 2014. [Link to publication]

Translational Pharmacokinetic Modeling of Fingolimod

Snelder N., Ploeger B.A., Luttringer O., Stanski D.R. and Danhof M., Translational Pharmacokinetic Modeling of Fingolimod (FTY720) as a Paradigm Compound Subject to Sphingosine Kinase-mediated Phosphorylation, Drug Metab Dispos, 25(113): 056770, 2014. [Link to publication]

Drug effects on the cardiovascular system in conscious rats

Snelder N., Ploeger B.A., Luttringer O., Rigel D.F., Fu F., Beil M., Stanski D.R. and Danhof M., Drug effects on the cardiovascular system in conscious rats – separating cardiac output into heart rate and stroke volume using PKPD modeling, Br J Pharmacol, 24(10): 12824, 2014. [Link to publication]

Pharmacokinetic-Pharmacodynamic Modeling of the Antihypertensive Effect of Eprosartan

van Rijn-Bikker P.C., Ackaert O., Snelder N., van Hest R.M., Ploeger B.A., Koopmans R.P. and Mathot R.A., Pharmacokinetic-Pharmacodynamic Modeling of the Antihypertensive Effect of Eprosartan in Black and White Hypertensive Patients, Clin Pharmacokinet, 22: 22, 2013. [Link to publication]

The impact of P-gp functionality

Westerhout J., Smeets J., Danhof M. and de Lange E.C., The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid, J Pharmacokinet Pharmacodyn, 29: 29, 2013. [Link to publication]

Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone

Reif S., Snelder N., and Blode H., Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study, J Fam Plann Reprod Health Care., 39(2): e1. doi: 10.1136/jfprhc-2012-100397., 2013. [Link to publication]

PKPD modelling of the interrelationship

Snelder N., Ploeger B.A., Luttringer O., Rigel D.F., Webb R.L., Feldman D., Fu F., Beil M., Jin L., Stanski D.R. and Danhof M., PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats, Br J Pharmacol., 169(7): 1510-1524. doi: 1510.1111/bph.12190., 2013. [Link to publication]

Evaluation of the Impact of UGT Polymorphism

Stringer F., Ploeger B.A., Jongh J.d., Scott G., Urquhart R., Karim A. and Danhof M., Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar, J Clin Pharmacol., 53(3): 256-263, 2013. [Link to publication]

Nonlinear mixed effects modeling of the diurnal blood pressure profile

van Rijn-Bikker P.C., Snelder N., Ackaert O., van Hest R.M., Ploeger B.A., van Montfrans G.A., Koopmans R.P. and Mathot R.A., Nonlinear mixed effects modeling of the diurnal blood pressure profile in a multiracial population, Am J Hypertens., 26(9): 1103-1113. 2013. [Link to publication]